ÂÜÀòÂÒÂ×

Appointed in 2018, Lisa Anson has led the transformation of Redx into a clinical-stage biotech with two programmes in clinical development and a growing pipeline of preclinical assets. During this time the company also secured major partnership deals for four assets with large and speciality pharma and secured long-term financing with new blue chip life science-focused investors.

Prior to joining Redx, Lisa had significant leadership experience in global pharmaceuticals over a 20-year career at AstraZeneca plc with her appointment in 2012 as President of AstraZeneca UK having held a series of senior commercial leadership roles in the company in both the US and the UK. Lisa is also a key player in the industry, and in 2018 she was elected to the Board of the BioIndustry Association (BIA). Previously Lisa has been President of the Association of the British Pharmaceutical Industry (ABPI) and a member of the board, where she chaired several UK industry committees and worked closely with the UK Government. Lisa started her career as a management consultant in London before moving to California with a cancer disease management company,

Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First-Class honours degree in Natural Sciences from Cambridge University in the UK.